secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cardiff Oncology, Inc. (CRDF)
CIK:        0001213037
Form:       8-K
Filed at:   2025-06-26T23:59:59+00:00
Accession:  0001641172-25-016659
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Cardiff Oncology stockholders approve all proposals at 2025 annual meeting
--------------------------------------------------------------------------

- Seven director nominees elected, including CEO Mark Erlander, with between 20.4M and 21.2M votes each.
- Ratification of BDO USA as independent auditor for FY2025: 36.3M for, 1.2M against.
- Amendment to 2021 Equity Incentive Plan approved (16.9M for, 5.0M against); shares available increased to 12.15M.
- Advisory say-on-pay vote on named executive officer compensation approved (18.9M for, 2.6M against).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213037/000164117225016659/0001641172-25-016659-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213037/000164117225016659/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-016659

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer